A Phase I, open-label study of Trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 12, Issue 3, 2014, Pages

  Hong, David S ^a   Gordon, Michael S ^b   Samlowski, Wolfram E ^c   Kurzrock, Razelle ^a   Tannir, Nizar ^a   Friedland, David ^d   Mendelson, David S ^b   Vogelzang, Nicholas J ^c   Rasmussen, Erik ^e   Wu, Benjamin M ^e   Bass, Michael B ^e   Zhong, Zhandong D ^e   Friberg, Gregory ^e   Appleman, Leonard J ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b Pinnacle Oncology Hematology   (United States)

^c Comprehensive Cancer Centers of Nevada and US Oncology ^*  (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e AMGEN INC   (United States)

Author keywords

Angiogenesis; Angiopoietins; Targeted therapies; Tie2 receptor; Vascular growth factor receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BIOLOGICAL MARKER; CREATININE; SORAFENIB; SUNITINIB; TREBANANIB; ANGIOGENIC PROTEIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; HYBRID PROTEIN; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE; TRENANANIB; TUMOR MARKER;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLISTER; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPHONIA; EPISTAXIS; ERYTHEMA; EVALUATION STUDY; FACE EDEMA; FATIGUE; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GENERALIZED EDEMA; GLOSSODYNIA; HAND FOOT SYNDROME; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERKERATOSIS; HYPERTENSION; HYPERURICEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY FAILURE; LACRIMATION DISORDER; LEUKOPENIA; LIMB PAIN; LUNG EMBOLISM; MALE; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PROTEINURIA; PRURITUS; RASH; SEPSIS; SIDE EFFECT; SKIN DISEASE; SKIN EXFOLIATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENIC PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84900319173     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.11.007     Document Type: Article

References (36)

1. J. Medioni, E. Banu, and D. Helley et al. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series Eur Urol 56 2009 207 211
2. D.R. Feldman, M.S. Baum, and M.S. Ginsberg et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1432 1439
3. J. Sosman, and I. Puzanov Combination targeted therapy in advanced renal cell carcinoma Cancer 115 2009 2368 2375
4. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286
5. P.C. Maisonpierre, C. Suri, and P.F. Jones et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 1997 55 60
6. C. Suri, P.F. Jones, and S. Patan et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87 1996 1171 1180
7. G. Bunone, P. Vigneri, and L. Mariani et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features Am J Pathol 155 1999 1967 1976
8. T. Etoh, H. Inoue, and S. Tanaka et al. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma Cancer Res 61 2001 2145 2153
9. C. Sfiligoi, A. de Luca, and I. Cascone et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival Int J Cancer 103 2003 466 474
10. A.J. Bullock, L. Zhang, and A.M. O'Neill et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC) J Clin Oncol 28 2010 (abstract 4630)
11. A. Coxon, J. Bready, and H. Min et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody Mol Cancer Ther 9 2010 2641 2651
12. R.S. Herbst, D. Hong, and L. Chap et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors J Clin Oncol 27 2009 3557 3565
13. B.Y. Karlan, A.M. Oza, and G.E. Richardson et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer J Clin Oncol 30 2012 362 371
14. S.M. Wilhelm, C. Carter, and L. Tang et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
15. L.Q. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 2007 884 896
16. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
17. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
18. Z.D. Zhong, S. Dinnogen, and M. Hokom et al. Identification and inhibition of drug target interference in immunogenicity assays J Immunol Methods 355 2010 21 28
19. M.B. Bass, S.I. Sherman, and M.J. Schlumberger et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer J Clin Endocrinol Metab 95 2010 5018 5027
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. M.B. Atkins, A. Ravaud, and G. Gravis et al. Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study J Clin Oncol 30 2012 (abstract 4606)
22. B. Rini, C. Szczylik, and N.M. Tannir et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study Cancer 118 2012 6152 6161
23. J.F. Lu, E. Rasmussen, and B.Y. Karlan et al. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection Cancer Chemother Pharmacol 69 2012 1135 1144
24. B.I. Rini, and M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol 10 2009 992 1000
25. J.M. Ebos, C.R. Lee, and R.S. Kerbel Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy Clin Cancer Res 15 2009 5020 5025
26. O. Casanovas, D.J. Hicklin, and G. Bergers et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
27. J. Huang, J.O. Bae, and J.P. Tsai et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade Int J Oncol 34 2009 79 87
28. F. Winkler, S.V. Kozin, and R.T. Tong et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563
29. A.A. van der Veldt, L. Vroling, and R.R. de Haas et al. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer Int J Cancer 131 2012 E484 E493
30. S.E. Deprimo, C.L. Bello, and J. Smeraglia et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins J Transl Med 5 2007 32
31. B.I. Rini, M.D. Michaelson, and J.E. Rosenberg et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748
32. D.D. Dahlen, N.L. Lin, and Y.C. Liu et al. Soluble Kit receptor blocks stem cell factor bioactivity in vitro Leuk Res 25 2001 413 421
33. P. Bono, A. Krause, and M. von Mehren et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib Blood 103 2004 2929 2935
34. S.E. Deprimo, X. Huang, and M.E. Blackstein et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure Clin Cancer Res 15 2009 5869 5877
35. H.L. Zhang, Y. Zhu, and X.J. Qin et al. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature Clin Genitourin Cancer 11 2013 134 140
36. A. Adini, T. Kornaga, and F. Firoozbakht et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages Cancer Res 62 2002 2749 2752